Drugs / ACTH
last change Jan 2024 re-read 2 minutes ago

ACTH

targets MC2R via activation

Developed for
lupus nephritis

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02226341 Comparator Oct 2014 → Jan 2024 lupus nephritis Columbia University Terminated No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ACTH ClinicalTrials.gov intervention name — accepted as the source's own label NCT02226341
Action Activate “ACTH binding to melanocortin 2 receptor subtype (MC2R) on the adrenal cortex stimulates the production of cortisol that reduces inflammation in the kidney.” NCT02226341
Route Subcutaneous “80 U biw, subcutaneousNCT02226341
Target MC2R “ACTH binding to melanocortin 2 receptor subtype (MC2R)” NCT02226341